Advancements in Indolent Systemic Mastocytosis Treatments Offer New Hope
The treatment landscape for indolent systemic mastocytosis (ISM) is evolving, with new therapies showing promise for patients experiencing persistent symptoms. Recent clinical experiences with the targeted therapy avapritinib have fostered…